|Bid||8.28 x 1000|
|Ask||8.50 x 1000|
|Day's Range||8.10 - 8.39|
|52 Week Range||2.60 - 9.84|
|Beta (5Y Monthly)||-0.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.09|
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.